References

Unresolved reference

External reference

Determinants of Survival After First Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

10.1038/s41375-024-02395-4 · 2024 · External reference

Survival Following Relapse in Children With Acute Myeloid Leukemia: A Report From AML‐BFM and COG

10.3390/cancers13102336 · 2021 · External reference

Pre‐Transplant Levels of Multiparametric Flow‐Cytometry Measurable Residual Disease (MFC‐MRD) Predict Outcomes in Children With Acute Myeloid Leukemia Given Allogeneic Hematopoietic Stem Cell Transplantation

10.1182/blood-2023-189080 · 2023 · External reference

Pre‐ and Post‐Transplant Minimal Residual Disease Predicts Relapse Occurrence in Children With Acute Lymphoblastic Leukaemia

10.1111/bjh.15086 · 2018 · External reference

Venetoclax and Navitoclax in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

10.1158/2159-8290.cd-20-1465 · 2021 · External reference

Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

10.1002/pbc.31630 · 2025 · External reference

Venetoclax in Combination With Cytarabine With or Without Idarubicin in Children With Relapsed or Refractory Acute Myeloid Leukaemia: A Phase 1, Dose‐Escalation Study

10.1016/s1470-2045(20)30060-7 · 2020 · External reference

Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia

10.1002/pbc.31714 · 2025 · External reference

Venetoclax: A New Player in the Treatment of Children With High‐Risk Myeloid Malignancies?

10.1182/bloodadvances.2023012041 · 2024 · External reference

Single‐Center Pediatric Experience With Venetoclax and Azacitidine as Treatment for Myelodysplastic Syndrome and Acute Myeloid Leukemia

10.1002/pbc.28398 · 2020 · External reference

Venetoclax for Children and Adolescents With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

10.3390/cancers14010150 · 2022 · External reference

Venetoclax‐Based Therapy as a Bridge to Allogeneic Hematopoietic Cell Transplantation in Children With Relapsed/Refractory AML

10.1038/s41409-022-01877-2 · 2023 · External reference

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

10.3390/cancers15071983 · 2023 · External reference

Clinical Responses in Pediatric Patients With Relapsed/Refractory Leukemia Treated With Azacitidine and Venetoclax

10.3324/haematol.2022.282637 · 2023 · External reference

Venetoclax in Combination With Chemotherapy as Treatment for Pediatric Advanced Hematologic Malignancies

10.1002/pbc.30335 · 2023 · External reference

Venetoclax‐Based Therapies in Pediatric Advanced MDS and Relapsed/Refractory AML: A Multicenter Retrospective Analysis

10.1182/bloodadvances.2023010113 · 2023 · External reference

ITCC‐101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin With or Without Venetoclax in Children With Relapsed Acute Myeloid Leukemia

10.1182/blood-2025-1656 · 2025 · External reference

Development and Inter‐Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool

10.1371/journal.pone.0028096 · 2011 · External reference

Venetoclax Responses of Pediatric All Xenografts Reveal Sensitivity of MLL‐Rearranged Leukemia

10.1182/blood-2016-03-707414 · 2016 · External reference

Single‐Cell Multiomics Reveal the Scale of Multilayered Adaptations Enabling CLL Relapse During Venetoclax Therapy

10.1182/blood.2022016040 · 2022 · External reference